
ThermoGenesis Holdings THMO
Quarterly report 2024-Q1
added 05-17-2024
ThermoGenesis Holdings Book Value 2011-2026 | THMO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value ThermoGenesis Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.32 M | 3.4 M | 5.87 M | 916 K | 6.73 M | 30.8 M | 32.3 M | 34.9 M | 48.7 M | 13.3 M | 15.9 M | 20.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48.7 M | 916 K | 18 M |
Quarterly Book Value ThermoGenesis Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.09 M | -3.58 M | 3.26 M | 2.63 M | 5.01 M | 3.32 M | 4.27 M | 5.51 M | 1.28 M | 3.4 M | 6.17 M | 7.87 M | 10.4 M | 5.87 M | 5.87 M | 5.87 M | 5.87 M | 916 K | 916 K | 916 K | 916 K | 6.73 M | 6.73 M | 6.73 M | 6.73 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 33.7 M | 36.3 M | 32.3 M | 32.3 M | 32.2 M | 32.3 M | 34.9 M | 34.9 M | 56 M | 45 M | 48.7 M | 62.9 M | 14.3 M | 16.5 M | 18.5 M | 18.5 M | 20.6 M | 20.8 M | 21.1 M | 21.1 M | 22.3 M | 23.4 M | 24.4 M | 24.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62.9 M | -3.58 M | 18.2 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 13.38 | 2.29 % | $ 1.81 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
50.1 M | $ 3.28 | 1.86 % | $ 123 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.6 | -1.96 % | $ 37.3 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 11.08 | -1.16 % | $ 314 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | $ 25.74 | -1.0 % | $ 218 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 90.74 | -3.16 % | $ 12.3 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.08 | -1.89 % | $ 1.26 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 5.16 | -5.84 % | $ 1.09 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.14 | -4.3 % | $ 355 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 10.55 | -2.68 % | $ 378 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.04 | -3.7 % | $ 17.6 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.79 | -2.85 % | $ 1.14 B | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 61.29 | -3.34 % | $ 3.34 B | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 55.11 | 0.07 % | $ 1.62 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.35 | 2.69 % | $ 64 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 84.64 | -0.83 % | $ 2.94 B | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.23 | -4.3 % | $ 50 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 82.28 | -1.41 % | $ 48.1 B | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.4 | 1.8 % | $ 502 M | ||
|
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | ||
|
NanoVibronix
NAOV
|
33.5 M | - | - | $ 1.08 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.82 | -1.19 % | $ 34.3 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Natus Medical Incorporated
NTUS
|
425 M | - | 1.94 % | $ 1.05 B | ||
|
Orthofix Medical
OFIX
|
450 M | $ 11.91 | -3.33 % | $ 472 M |